Skip to main content

Table 1 Comparative intrinsic activity: Range (mg/l) of MIC50 and MIC90 from published studies

From: Revisiting cefditoren for the treatment of community-acquired infections caused by human-adapted respiratory pathogens in adults

  References Amoxicillin/clavulanic acid Cefuroxime Cefditoren
MIC50 MIC90 MIC50 MIC90 MIC50 MIC90
Streptococcus pyogenes a 13–15 ≤0.012–0.06 ≤0.012–0.12 0.03–0.06 0.12 ≤0.03 ≤0.03–0.06
Streptococcus pneumoniae b 14,15,41–48       
 Penicillin-susceptible   ≤0.015–0.06 0.03–0.25 ≤0.03 0.12–0.25 ≤0.015 ≤0.03–0.06
 Penicillin-intermediate   0.25–1 1–4 0.5–4 4–8 0.06–0.25 0.25–0.5
 Penicillin-resistant   2 - ≥16 8 - ≥16 4–8 8–32 0.25–0.5 0.5–1
Haemophilus influenzae
 β-lactamase negative 14,15,22,41,44 0.25–1 1–8 0.25–2 1–8 ≤0.08 ≤0.03–0.06
 β-lactamase positive 14,15,22,41,44 0.5–2 2–4 1–2 2–8 ≤0.08 ≤0.03–0.06
 BLNAR 14,15,65 2 4 0.5–4 2–16 ≤0.08 0.03–0.06
 BLPACR 65 4 8 4 16 0.03 0.06
Moraxella catarrhalis (β-lactamase positive) 14,15,22,23 0.12–0.5 0.25–2 1 2–8 0.06–0.12 0.25–0.5
  1. aIn terms of ampicillin (ref. [13])
  2. bIn terms of amoxicillin (ref. [14, 15, 43,44,45,46])